

OncoGeneDx: Endometrial Cancer Panel

Panel Gene List: *BRCA1, BRCA2, CHEK2, EPCAM**, *MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, PTEN, TP53*

*Testing includes sequencing and deletion/duplication analysis for all genes except *EPCAM* (del/dup only).

Clinical Features:

Women in the general population have approximately a 5% lifetime risk to develop endometrial cancer, also known as uterine cancer (SEER). Most cases of endometrial cancer develop sporadically. However, approximately 5-10% of endometrial cancer cases are due to a hereditary predisposition. The features of a personal and/or family history of cancer that are suggestive of a hereditary cancer predisposition include: young ages at diagnosis, multiple primary cancers in a single individual, and several relatives affected with related cancers spanning multiple generations.

Of the cases that are suspected of having a hereditary predisposition to endometrial cancer, approximately 2-3% are associated with Lynch syndrome due to pathogenic variants in the *MLH1, MSH2, MSH6, or PMS2* genes (Hampel 2007). A subset of individuals with Lynch syndrome carry exon-level deletions in the 3' end of the *EPCAM* gene (Tutlewska 2013). Approximately 5% of individuals with uterine serous carcinoma have a pathogenic variant in a non-Lynch syndrome associated gene (Pennington 2013). The additional 7 genes on this panel besides the Lynch syndrome genes account for additional causes of hereditary endometrial cancer cases. All of these genes are associated with increased risk of endometrial cancer and, in many cases, other cancers as well. Newer genes that have been identified in families with endometrial cancer have been included in the panel to make it as comprehensive as possible. These genes include *CHEK2* and *POLD1*. The evidence available to date may be derived from a small number of patients with wide confidence intervals or is based upon an ethnic cohort with one specific variant. Accurate risk assessment may be complicated by the low penetrance of pathogenic variants in these genes and/or ascertainment bias.

Inheritance Pattern:

Most genes on this panel are associated with an autosomal dominant cancer risk with the exception of *MUTYH*, which is associated with an autosomal recessive cancer risk. Some of the genes on this panel are also associated with extremely rare conditions when inherited in an autosomal recessive fashion. The specifics of this inheritance are outlined in the table below.

Test Methods:

Genomic DNA from the submitted specimen is enriched for the complete coding region and splice site junctions of the genes on the panel using a proprietary targeted capture system

developed by GeneDx. (For *PTEN*, nucleotides c.-700 through c.-1300 in the promoter region are also captured.) The products are sequenced on an Illumina HiSeq instrument with 2x100 paired-end reads. The sequence is aligned to reference sequences based on human genome build GRCh37/UCSC hg19. Capillary sequencing is used to confirm all variants with clinical or uncertain significance and to analyze regions with inadequate coverage by Next Generation sequencing (NGS). If present, apparently homozygous variants are confirmed using alternate primer pairs to significantly reduce the possibility of allele drop-out. All sequence alterations are described according to the Human Genome Variation Society (HGVS) nomenclature guidelines. Concurrent deletion/duplication analysis from NGS data is performed for all relevant genes on the panel to detect multi-exonic and most single-exon deletions and duplications. For specimens with insufficient copy number data and for confirmation of identified copy number changes, exon-level array CGH, MLPA or other appropriate methods are used. For *EPCAM*, deletion/duplication analysis, but not sequencing, is performed. Copy-number alterations are reported according to the International System for Human Cytogenetic Nomenclature (ISCN) guidelines. Benign and likely benign variants, if present, are not reported but are available upon request. Data analysis is performed using gene-specific filtering; the genes evaluated by this test are listed on the first page of the report.

Test Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the 12 genes included in the OncoGeneDx Endometrial Cancer Panel depends in part on the patient's clinical phenotype and family history. In general, the sensitivity is highest for individuals with features suggestive of hereditary predisposition to cancer as outlined above. DNA sequencing will detect nucleotide substitutions and small insertions and deletions, while NGS-CNV analysis, array CGH, or MLPA will detect exon-level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or CNV technology. The likelihood of a false positive result is expected to be <1%.

Technical Limitations: Neither sequencing, exon-level array CGH nor MLPA can reliably detect mosaicism, and cannot detect chromosomal aberrations. Deletions involving more than 20bp and insertions involving more than 10bp are not reliably detected by the sequencing methodology, and deletions or duplications of less than 250bp are not reliably detected by NGS-CNV analysis or array CGH. Regions of certain genes have inherent sequence properties that yield suboptimal data, potentially impairing accuracy of the results. For instance, sequence and deletion/duplication analysis of *PMS2* and *CHEK2*, among others, is complicated by the presence of pseudogenes or homologous sequences that involve multiple exons of these genes. In the absence of mRNA/cDNA studies, we cannot completely exclude the possibility of undetectable clinically significant variants in certain regions of these genes. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In individuals with active leukemia or lymphoma or with

known chronic myeloid or lymphoid neoplasms (such as low grade MDS, CML, ET, P. vera, PMF, CLL), there is a possibility that testing of specimens containing leukocytes may detect an acquired somatic variant, resulting in a false positive result. In this situation, please contact one of our genetic counselors to discuss the utility of submitting an alternate specimen. The ability to detect genetic variants and naming conventions can differ among laboratories. Rare false negatives, therefore, may occur when testing for a specific variant identified at a laboratory other than GeneDx, if a positive control is not provided. Based on the specific array design and technology used, the reported coordinates of duplications and deletions at the exon or gene level can slightly differ among family members tested but, in general, relatives are expected to have the same copy number variant.

Gene	Protein	Inheritance	Disease Associations
<i>BRCA1</i>	BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN	AD	Hereditary Breast and Ovarian Cancer (HBOC) syndrome: breast, ovarian, pancreatic, prostate & endometrial serous cancer
<i>BRCA2</i>	BREAST CANCER TYPE 2 SUSCEPTIBILITY PROTEIN	AD	Hereditary Breast and Ovarian Cancer (HBOC) syndrome: breast, ovarian, pancreatic, prostate, melanoma & endometrial serous cancer
		AR	Fanconi Anemia
<i>CHEK2</i>	SERINE/THREONINE-PROTEIN KINASE CHK2	AD	Breast, colon, prostate, thyroid, endometrial & ovarian cancer
<i>EPCAM</i>	EPITHELIAL CELL ADHESION MOLECULE	AD	Lynch syndrome: colorectal, endometrial, ovarian, gastric pancreatic, biliary tract, urinary tract, small bowel & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MLH1</i>	DNA MISMATCH REPAIR PROTEIN MLH1	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, Biliary tract, Urinary tract, small bowel & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome

<i>MSH2</i>	DNA MISMATCH REPAIR PROTEIN MSH2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, urinary tract, pancreatic, biliary tract, small bowel & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MSH6</i>	DNA MISMATCH REPAIR PROTEIN MSH6	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, small bowel & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MUTYH</i>	ADENINE DNA GLYCOSYLASE	AR	<i>MUTYH</i> -associated polyposis (MAP): colorectal, small bowel & endometrial serous cancer, gastrointestinal polyps
<i>PMS2</i>	MISMATCH REPAIR ENDONUCLEASE PMS2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>POLD1</i>	DNA POLYMERASE DELTA CATALYTIC SUBUNIT	AD	Colon & endometrial cancer, colon polyps
<i>PTEN</i>	PHOSPHATIDYLINOSITOL 3,4,5- TRISPHOSPHATE 3- PHOSPHATASE AND DUAL- SPECIFICITY PROTEIN PHOSPHATASE PTEN	AD	<i>PTEN</i> hamartoma tumor syndrome (PHTS): breast, thyroid, endometrial, colon, melanoma & renal cancer, gastrointestinal polyps, Lhermitte-Duclos Disease
<i>TP53</i>	CELLULAR TUMOR ANTIGEN P53	AD	Li-Fraumeni syndrome (LFS): breast cancer, sarcoma, brain cancer, hematologic malignancies, adrenocortical carcinoma, among others**

Because of evolving and expanding phenotypes, this list of cancer/tumor types is not exhaustive. Gene-specific risk for some of the cancers and other features listed are not well-defined.

** High overall risk of cancer: 75% lifetime risk for males to develop cancer, nearly 100% risk for females.

Abbreviations:

AD – Autosomal Dominant
AR – Autosomal Recessive

CGH – Comparative genomic hybridization
MLPA - Multiplex ligation-dependent probe amplification

References:

1. Antoniou A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 2003 May;72(5):1117-30. (PMID 12677558)
2. Baglietto L et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst.* 2010 Feb;102(3):193-201. (PMID: 20028993)
3. Balaguer F et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol.* 2007;5:379–87. (PMID: 17368238)
4. Barnetson RA et al. Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. *Clin Genet.* 2007 Dec;72(6):551-5. (PMID: 17956577)
5. Biron-Shental T et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. *Eur J Surg Oncol.* 2006 Dec;32(10):1097-100. (PMID 16650962)
6. Bonadona V et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA.* 2011 Jun;305(22):2304-10. (PMID: 21642682)
7. Bonpari KS et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology.* 2008 Dec;135(6):2014-8. (PMID: 19013464)
8. Chen S and Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol.* 2007 Apr;25(11):1329-33. (PMID 17416853)
9. Chompret A et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br J Cancer.* 2000 Jun;82(12):1932-7. (PMID 10864200)
10. Cleary SP et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology.* 2009;136:1251–60. (PMID: 19245865)
11. Croitoru ME et al. Association Between Biallelic and Monoallelic Germline MYH Gene Mutations and Colorectal Cancer Risk. *JNCI.* 2004;96:1631–4. (PMID: 15523092)
12. Cunningham JM et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. *Am J Hum Genet.* 2001 Oct;69(4):780-90. (PMID: 11524701)
13. Cybulski C et al. CHEK2 is a multiorgan cancer susceptibility gene. *Am J Hum Genet.* 2004 Dec;75(6):1131-5. (PMID 15492928)
14. Dong X et al. Mutations in CHEK2 associated with prostate cancer risk. *Am J Hum Genet.* 2003 Feb;72(2):270-80. (PMID 12533788)
15. Durso CA et al. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. *Am J Gastroenterol.* 2010 Nov;105(11):2449-56. (PMID: 20531397)
16. Einarsdóttir K et al. Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. *Hum Mol Genet.* 2007 Jan 15;16(2):154-64. (PMID 17164260)
17. Farrington SM et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. *Am J Hum Genet.* 2005;77:112–9. (PMID: 15931596)
18. Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet.* 1998 Mar;62(3):676-89. (PMID 9497246)
19. Gonzalez PD et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol.* 2009 Mar 10;27(8):1250-6. (PMID 19204208)
20. Graeser MK et al. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *J Clin Oncol.* 2009 Dec 10;27(35):5887-92. (PMID 19858402)
21. Hampel et al. Comment on: screening for Lynch Syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res.* 2007;67:9603. (PMID 17909073)
22. Han FF et al. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol.* 2013 Jun;32(6):329-35. (PMID 23713947)
23. Hisada M et al. Multiple primary cancers in families with Li-Fraumeni syndrome. *J Natl Cancer Inst.* 1998 Apr 15;90(8):606-11. (PMID 9554443)
24. Hobert JA and Eng C. PTEN hamartoma tumor syndrome: An overview. *Genet Med* 2009;11(10):687– 694. (PMID 19668082)
25. Jasperson KW et al. Hereditary and Familial Colon Cancer. *Gastroenterology.* 2010 Jun;138(6):2044-58 (PMID: 20420945)
26. Jasperson KW. Genetic testing by cancer site: colon (polyposis syndromes). *Cancer J.* 2012 Jul-Aug;18(4):328-33. (PMID: 22846733)
27. Jenkins MA et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. *Cancer Epidemiol Biomarkers Prev.* 2006;15:312-14. (PMID: 16492921)
28. Kilpivaara O et al. CHEK2 I157T associates with familial and sporadic colorectal cancer. *J Med Genet.* 2006 Jul;43(7):e34. (PMID 16816021)
29. King MC et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science.* 2003 Oct;302(5645):643-6. (PMID 14576434)
30. Leide A et al. Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature. *J Clin Oncol.* 2004 Feb 15;22(4):735-42. (PMID 14966099)

31. Levine DA et al. Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations. *J Clin Oncol*. 2003 Nov 15;21(22):4222-7. (PMID 14615451)
32. Liu C et al. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. *Asian Pac J Cancer Prev*. 2012;13(5):2051-5. (PMID 22901170)
33. Li-Chang HH et al. Colorectal cancer in a 9-year-old due to combined EPCAM and MSH2 germline mutations: case report of a unique genotype and immunophenotype. *J Clin Pathol*. 2013 Jul;66(7):631-3. (PMID: 23454724)
34. Lubbe SJ et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutations. *J Clin Oncol*. 2009;27:3975-80. (PMID: 19620482)
35. National Cancer Institute at the National Institutes of Health. What you need to know about: cancer; risk factors. (URL: <http://www.cancer.gov/about-cancer>) [February 2016 accessed].
36. Olivier M et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res*. 2003 Oct 15;63(20):6643-50. (PMID 14583457)
37. Out AA et al. MUTYH gene variants and breast cancer in a Dutch case-control study. *Breast Cancer Res Treat*. 2012 Jul;134(1):219-27. (PMID: 22297469)
38. Pennington KP et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. *Cancer*. 2013 Jan;119(2):332-8. (PMID 22811390)
39. Quehenberger F et al. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet*. 2005 Jun;42(6):491-6. (PMID: 21642682)
40. Rahman N et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet*. 2007 Feb;39(2):165-7. (PMID 17200668)
41. Rasool S et al. A comparative overview of general risk factors associated with the incidence of colorectal cancer. *Tumour Biol*. 2013 Oct;34(5):2469-76. (PMID 23832537)
42. Rennert G et al. MutYH mutation carriers have increased breast cancer risk. *Cancer*. 2012 Apr;118(8):1989-93. (PMID: 21952991)
43. Risch HA et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario. *J Natl Cancer Inst*. 2006 Dec;98(23):1694-706. (PMID 17148771)
44. Ruijs MWG et al. TP53 germline mutation testing in 180 families suspected of LieFraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. *J Med Genet*. 2010 Jun;47(6):421-8. (PMID 20522432)
45. Santonocito C et al. Common genetic variants of MUTYH are not associated with cutaneous malignant melanoma: application of molecular screening by means of high-resolution melting technique in a pilot case-control study. *Int J Biol Markers*. 2011 Jan-Mar;26(1):37-42. (PMID: 21279954)
46. Saslow D et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. *CA Cancer J Clin*. 2007 May-Jun; 57(3):185. (PMID 17392385)
47. Senter L et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology*. 2008 Aug;135(2):419-28. (PMID: 18602922)
48. Setiawan VW et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? *J Clin Oncol*. 2013 Jul 10;31(20):2607-18. (PMID 23733771)
49. Seppala EH et al. CHEK2 variants associate with hereditary prostate cancer. *Br J Cancer*. 2003 Nov 17;89(10):1966-70. (PMID 14612911)
50. Sieber OM et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med*. 2003 Feb 27;348(9):791-9. (PMID: 12606733)
51. Suchy J et al. CHEK2 mutations and HNPCC-related colorectal cancer. *Int J Cancer*. 2010 Jun 15;126(12):3005-9. (PMID 19876921)
52. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. SEER Cancer Statistics Review, 1975-2012: Lifetime Risk Tables (URL: <http://surveillance.cancer.gov/devcan>) [February 2016 accessed].
53. The CHEK2 Breast Cancer Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet*. 2004 Jun;74(6):1175-82. (PMID 15122511)
54. Tuttlewska K, Lubinski J, and Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review. *Hered Cancer Clin Pract*. 2013;11(1):9. (PMID 23938213)
55. van der Groep P, van der Wall E, and van Diest PJ. Pathology of hereditary breast cancer. *Cell Oncol (Dordrecht)*. 2011 Apr;34(2):71-88. (PMID: 21336636)
56. Vasen HF et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology*. 1996 Apr;110(4):1020-7. (PMID: 8612988)
57. Vogt S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology*. 2009;137:1976-85. (PMID: 19732775)
58. Walsh T et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci*. 2011 Nov;108(44):18032-7. (PMID: 22006311)
59. Weissman SM et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review. *J Genet Couns*. 2011 Feb;20(1):5-19. (PMID: 20931355)
60. Wimmer K et al. Constitutional mismatch repair-deficiency syndrome. *Haematologica*. 2010 May; 95(5): 699–701. (PMID: 20442441)
61. Win AK et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. *Int J Cancer*. 2011 Nov 1;129(9):2256-62. (PMID: 21171015)

62. Win AK et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012 Mar;30(9):958-64. (PMID: 22331944)